Authors: Faivre, S Raymond, E Boige, V Gatineau, M Buthaut, X Rixe, O Bernareggi, A Camboni, G Armand, JP

Citation: S. Faivre et al., A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies, CLIN CANC R, 7(1), 2001, pp. 43-50

Authors: Borchmann, P Schnell, R Knippertz, R Staak, JO Camboni, GM Bernareggi, A Hubel, K Staib, P Schulz, A Diehl, V Engert, A

Citation: P. Borchmann et al., Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma, ANN ONCOL, 12(5), 2001, pp. 661-667

Authors: Dawson, LK Jodrell, DI Bowman, A Rye, R Byrne, B Bernareggi, A Camboni, G

Citation: Lk. Dawson et al., A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly, EUR J CANC, 36(18), 2000, pp. 2353-2359

Authors: Sessa, C Capri, G Gianni, L Peccatori, F Grasselli, G Bauer, J Zucchetti, M Vigano, L Gatti, A Minoia, C Liati, P Van den Bosch, S Bernareggi, A Camboni, G Marsoni, S

Citation: C. Sessa et al., Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex, ANN ONCOL, 11(8), 2000, pp. 977-983